Der Urologe

, Volume 45, Issue 4, pp 496–498

Was gibt’s Neues beim Harnblasenkarzinom*

AUO

Literatur

  1. 1.
    Jocham D, Witjes F, Wagner S et al. (2005) Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174: 862–866 CrossRefPubMedGoogle Scholar
  2. 2.
    de Reijke TM, Kurth KH, Sylvester RJ et al. (2005) Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). J Urol 173: 405–409CrossRefPubMedGoogle Scholar
  3. 3.
    Kipp BR, Karnes RJ, Brankley SM et al. (2005) Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 173: 401–404CrossRefPubMedGoogle Scholar
  4. 4.
    Dyrskjot L, Zieger K, Kruhoffer M et al. (2005) A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 11: 4029–4036 CrossRefPubMedGoogle Scholar
  5. 5.
    Blaveri E, Simko JP, Korkola JE et al. (2005) Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Re 11: 4044–4055 CrossRefGoogle Scholar
  6. 6.
    Harisinghani MG, Barentsz J, Hahn PF et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 19:348: 2491–2499 CrossRefGoogle Scholar
  7. 7.
    Deserno WM, Harisinghani MG, Taupitz M et al. (2004) Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 233: 449–456 PubMedGoogle Scholar
  8. 8.
    Fleischmann A, Thalmann GN, Markwalder R, Studer UE (2005) Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 23: 2358–2365 CrossRefPubMedGoogle Scholar
  9. 9.
    Kurahashi T, Hara I, Oka N et al. (2005) Detection of micrometastases in pelvic lymph nodes in patients undergoing radical cystectomy for locally invasive bladder cancer by real-time reverse transcriptase-PCR for cytokeratin 19 and uroplakin II. Clin Cancer Res 11: 3773–3777 CrossRefPubMedGoogle Scholar
  10. 10.
    Retz MM, Sidhu SS, Blaveri E et al. (2005) CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int J Cancer 114: 182–189 CrossRefPubMedGoogle Scholar
  11. 11.
    Retz M, Sidhu SS, Lehmann J et al. (2005) New HIV-drug inhibits in vitro bladder cancer migration and invasion. Eur Urol 48: 1025–1030 CrossRefPubMedGoogle Scholar
  12. 12.
    Advanced Bladder Cancer (ABC) meta-analysis collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48: 202–205 CrossRefPubMedGoogle Scholar
  13. 13.
    Advanced Bladder Cancer (ABC) meta-analysis collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48: 189–199 CrossRefPubMedGoogle Scholar
  14. 14.
    Lehmann J, Retz M, Wiemers C et al. (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23: 4963–4974 CrossRefPubMedGoogle Scholar
  15. 15.
    Gschwend JE, Volkmer BG, Hautmann RE (2004) Radical cystectomy for bladder cancer in the neobladder era – progression and survival in 674 consecutive patients. J Urol 171: 304ACrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Klinik für Urologie und KinderurologieUrologische Universitätsklinik UlmUlm

Personalised recommendations